GSK Announces Positive CHMP Opinion For Meningitis B Booster

GSK announced the EMA's CHMP recommended updating Bexsero's label to include a single booster dose for people aged 10 and older, based on Phase IIIb study data. The study met its primary endpoint, showing immune response and safety. GSK's stock has a Hold rating with a $55.90 price target, and Spark rates it Neutral, citing solid financials and pipeline acceleration.

GSK plc announced that the European Medicines Agency's CHMP recommended adding a single booster dose for its MenB vaccine, Bexsero, for people aged 10 and older. The recommendation is based on a Phase IIIb trial showing a stronger immune response in previously vaccinated individuals. GSK shares were up 0.79% at 1,916p.

GSK's Bexsero meningitis B vaccine received a positive CHMP opinion for a single booster dose in individuals aged 10+ who were vaccinated at least two years prior. The recommendation was based on Phase IIIb study data showing immune memory can be boosted with a single dose. GSK shares rose 0.39% to 1,908.50p.

GSK received a positive EU recommendation for its Bexsero meningitis vaccine to include a single booster dose for individuals aged 10+ who were previously vaccinated. The recommendation is based on data showing immune memory can be boosted up to 19 years later. If adopted, this could reduce the burden of invasive meningococcal disease in Europe.

The NCCN updated its guidelines to include GSK's belantamab mafodotin (Blenrep) plus bortezomib and dexamethasone as a category 1 recommendation for lenalidomide-refractory multiple myeloma. The update also includes two other belantamab triplets under 'Useful in Certain Circumstances' for patients with 3 or more prior therapies. The changes follow the drug's FDA approval in October 2025 and reflect its efficacy in clinical trials.

The Liver Meeting 2026 highlighted advancements in hepatitis delta, PBC, and MASH treatments. Vir Biotechnology's elebsiran and Mirum Pharmaceuticals' brelovitug showed promising phase 3 results for hepatitis delta, with regulatory submissions expected in 2027. GSK's bepirovirsen received FDA approval for hepatitis B. Merck's efinopegdutide and Altimmune's pemvidutide showed potential in MASH treatment. Real-world data indicated cost concerns with MASH therapies.